Maxcyte (MXCT) Return on Capital Employed (2021 - 2026)

Maxcyte (MXCT) has 6 years of Return on Capital Employed data on file, last reported at 24.32% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 125.0% year-over-year to 24.32% in Q1 2026; TTM through Mar 2026 was 24.32%, a 125.0% decrease from a year earlier, with the FY2025 full-year figure at 25.1%, down 360.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 24.32%, up from 26.79% in the prior quarter.
• Over the last five years, Return on Capital Employed for MXCT reached as high as 5.87% in Q1 2022 and fell as low as 26.79% in Q4 2025.
• Historically, Return on Capital Employed has averaged 18.02% across 5 years, with a median of 19.09% in 2024.
• Across the five-year window, Return on Capital Employed slumped 39 bps in 2022 and sank 925 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 10.09% in 2022, then plunged by 92 bps to 19.35% in 2023, then declined by 16 bps to 22.43% in 2024, then dropped by 19 bps to 26.79% in 2025, then gained by 9 bps to 24.32% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 24.32% in Q1 2026, 26.79% in Q4 2025, and 26.72% in Q3 2025.